The rapid advancement of immunotherapy in recent years has presented a number of challenges to pharmaceutical firms looking to monitor and measure efficacy in patients.
With the advent of new targeted treatments and immunotherapies, Quintiles has provided clinical services for over 700 phase 1 and phase 2 oncology studies since 2011.
